We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

200 hedge funds and large institutions have $5.01B invested in Intercept Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 78 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 23

107% more capital invested

Capital invested by funds: $2.42B → $5.01B (+$2.58B)

47% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 53

18% more funds holding

Funds holding: 169200 (+31)

14% more call options, than puts

Call options by funds: $257M | Put options by funds: $225M

Holders
200
Holders Change
+31
Holders Change %
+18.34%
% of All Funds
5.33%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
54
Increased
78
Reduced
53
Closed
23
Calls
$257M
Puts
$225M
Net Calls
+$31.7M
Net Calls Change
+$71.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.01B +$82.1M +379,135 +12%
CG
2
Carmignac Gestion
France
$381M -$17.9M -82,684 -6%
O
3
OrbiMed
New York
$316M -$79M -365,000 -25%
Vanguard Group
4
Vanguard Group
Pennsylvania
$269M +$43.5M +200,898 +27%
Ameriprise
5
Ameriprise
Minnesota
$232M +$161M +745,603 +956%
Capital World Investors
6
Capital World Investors
California
$220M +$60M +277,142 +55%
First Trust Advisors
7
First Trust Advisors
Illinois
$180M +$78.2M +361,089 +130%
FAM
8
Fred Alger Management
New York
$136M +$48.3M +222,805 +86%
Jennison Associates
9
Jennison Associates
New York
$131M -$623K -2,879 -0.6%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$114M +$32.2M +148,885 +58%
BFA
11
BlackRock Fund Advisors
California
$111M +$10.6M +48,982 +14%
Millennium Management
12
Millennium Management
New York
$97M -$23.5M -108,541 -24%
BIT
13
BlackRock Institutional Trust
California
$92.7M +$2.15M +9,915 +3%
CWAM
14
Columbia Wanger Asset Management
Illinois
$89.1M -$16.9M -78,000 -20%
Franklin Resources
15
Franklin Resources
California
$77.8M -$68M -314,116 -53%
AWG
16
Alpha Wave Global
New York
$77.6M +$59.6M +275,000 New
JP Morgan Chase
17
JP Morgan Chase
New York
$77.4M +$47.6M +219,749 +401%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$68.9M -$21M -97,055 -28%
AGA
19
Altrinsic Global Advisors
Connecticut
$67.3M -$13.6M -63,009 -21%
State Street
20
State Street
Massachusetts
$64.4M -$7.93M -36,623 -14%
Credit Agricole
21
Credit Agricole
France
$48.8M -$866K -4,000 -2%
SAM
22
Sectoral Asset Management
Quebec, Canada
$46.5M -$3.66M -16,900 -9%
BB
23
BB Biotech
Switzerland
$43.7M +$33.6M +155,000 New
CCI
24
Columbus Circle Investors
$38M +$9.02M +41,647 +45%
Deutsche Bank
25
Deutsche Bank
Germany
$37.6M +$18.8M +86,628 +185%

ICPT Hedge Fund Activity: Q1 2015 in Review

200 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2015, worth a combined $5.01B — up 107% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new ICPT positions and 23 closed out — a net gain of 31 holders — while 78 added to existing stakes and 53 trimmed.

The largest buyer was Ameriprise, adding an estimated $161M. The largest seller was OrbiMed, cutting an estimated $79M.

  • 200 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2015, up from 169 in Q4 2014.
  • Funds reported $5.01B of Intercept Pharmaceuticals, Inc. stock for Q1 2015, up 107% quarter-over-quarter.
  • 54 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2015 and 23 closed out, a net change of +31 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2015 was Ameriprise, an estimated $161M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2015 was OrbiMed, an estimated $79M sold.

Based on aggregated 13F filings for Q1 2015.